Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 2 single-arm, open-label determining efficacy of Neo-adjuvant Abemaciclib and
Fulvestrant in subjects with Hormone receptor positive patients with localized non-metastatic
breast cancer who develop local recurrence while on adjuvant endocrine therapy with molecular
evidence of endocrine resistance.